New hope for Tough-to-Treat lung cancer
NCT ID NCT05020769
Summary
This study is testing whether adding a new investigational drug called SI-B001 to an existing lung cancer medication (osimertinib) is safe and effective for people with advanced non-small cell lung cancer that has worsened after prior treatment. It aims to find the best dose of the combination and see if it can help control the cancer. The study is for adults whose cancer has specific genetic features and who are in relatively good health otherwise.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center (SYSUCC)
Guangdong, Guangzhou, 510075, China
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Conditions
Explore the condition pages connected to this study.